Medico Remedies Limited (BOM:540937)
India
· Delayed Price · Currency is INR 40.47
-1.20 (-2.88%)
At close: Mar 9, 2026
Medico Remedies Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2016 |
| Operating Revenue | 1,909 | 1,509 | 1,449 | 1,404 | 1,210 | 1,224 | Upgrade
|
| Other Revenue | - | - | - | - | 0 | - | Upgrade
|
| Revenue | 1,909 | 1,509 | 1,449 | 1,404 | 1,210 | 1,224 | Upgrade
|
| Revenue Growth (YoY) | 26.44% | 4.15% | 3.19% | 16.04% | -1.12% | 38.08% | Upgrade
|
| Cost of Revenue | 1,412 | 1,102 | 1,112 | 1,057 | 887.41 | 934.6 | Upgrade
|
| Gross Profit | 497.07 | 407.01 | 336.79 | 347.51 | 322.8 | 289.3 | Upgrade
|
| Selling, General & Admin | 73.1 | 63.63 | 59.68 | 57.91 | 60.09 | 48.9 | Upgrade
|
| Other Operating Expenses | 258.56 | 193.35 | 148.02 | 193.41 | 188.98 | 188 | Upgrade
|
| Operating Expenses | 362.24 | 287.28 | 236.49 | 278.52 | 271.25 | 253.4 | Upgrade
|
| Operating Income | 134.83 | 119.73 | 100.3 | 68.99 | 51.55 | 35.9 | Upgrade
|
| Interest Expense | -10.92 | -8.54 | -6.43 | -5.8 | -5.07 | -7.9 | Upgrade
|
| Interest & Investment Income | 1.05 | 1.05 | 0.94 | 1.01 | 0.7 | 4.2 | Upgrade
|
| Currency Exchange Gain (Loss) | 25.85 | 25.85 | 20.31 | 38.46 | 19.59 | 6.1 | Upgrade
|
| Other Non Operating Income (Expenses) | 3.59 | -3.04 | -1.81 | -1.67 | -1.56 | -1.3 | Upgrade
|
| EBT Excluding Unusual Items | 154.39 | 135.04 | 113.32 | 100.99 | 65.22 | 37 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | 0.03 | - | -0.39 | - | Upgrade
|
| Pretax Income | 154.39 | 135.04 | 113.35 | 100.99 | 64.83 | 37 | Upgrade
|
| Income Tax Expense | 38.4 | 34.11 | 30.44 | 28.57 | 16.71 | 11.1 | Upgrade
|
| Net Income | 115.99 | 100.93 | 82.91 | 72.42 | 48.12 | 25.9 | Upgrade
|
| Net Income to Common | 115.99 | 100.93 | 82.91 | 72.42 | 48.12 | 25.9 | Upgrade
|
| Net Income Growth | 31.04% | 21.74% | 14.49% | 50.49% | 85.79% | 58.86% | Upgrade
|
| Shares Outstanding (Basic) | 83 | 83 | 83 | 83 | 83 | 83 | Upgrade
|
| Shares Outstanding (Diluted) | 83 | 83 | 83 | 83 | 83 | 83 | Upgrade
|
| Shares Change (YoY) | -0.80% | - | - | - | - | - | Upgrade
|
| EPS (Basic) | 1.40 | 1.22 | 1.00 | 0.87 | 0.58 | 0.31 | Upgrade
|
| EPS (Diluted) | 1.40 | 1.22 | 1.00 | 0.87 | 0.58 | 0.31 | Upgrade
|
| EPS Growth | 32.10% | 21.74% | 14.84% | 50.03% | 85.79% | 58.86% | Upgrade
|
| Free Cash Flow | - | 17.05 | -0.4 | 15.75 | -0.51 | -282.7 | Upgrade
|
| Free Cash Flow Per Share | - | 0.20 | -0.01 | 0.19 | -0.01 | -3.41 | Upgrade
|
| Gross Margin | 26.04% | 26.96% | 23.24% | 24.75% | 26.67% | 23.64% | Upgrade
|
| Operating Margin | 7.06% | 7.93% | 6.92% | 4.91% | 4.26% | 2.93% | Upgrade
|
| Profit Margin | 6.08% | 6.69% | 5.72% | 5.16% | 3.98% | 2.12% | Upgrade
|
| Free Cash Flow Margin | - | 1.13% | -0.03% | 1.12% | -0.04% | -23.10% | Upgrade
|
| EBITDA | 161.3 | 145.33 | 124.75 | 92.05 | 72.35 | 52.4 | Upgrade
|
| EBITDA Margin | 8.45% | 9.63% | 8.61% | 6.55% | 5.98% | 4.28% | Upgrade
|
| D&A For EBITDA | 26.47 | 25.61 | 24.45 | 23.05 | 20.8 | 16.5 | Upgrade
|
| EBIT | 134.83 | 119.73 | 100.3 | 68.99 | 51.55 | 35.9 | Upgrade
|
| EBIT Margin | 7.06% | 7.93% | 6.92% | 4.91% | 4.26% | 2.93% | Upgrade
|
| Effective Tax Rate | 24.87% | 25.26% | 26.86% | 28.29% | 25.77% | 30.00% | Upgrade
|
| Revenue as Reported | 1,942 | 1,536 | 1,470 | 1,444 | 1,231 | 1,234 | Upgrade
|
| Advertising Expenses | - | 0.86 | 0.47 | 0.37 | 5.66 | 3.9 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.